nach oben

Cancer Immunology, Immunotherapy

Erschienen in:

01.01.2016 | Original Article

Low intratumoral regulatory T cells and high peritumoral CD8⁺ T cells relate to long-term survival in patients with pancreatic ductal adenocarcinoma after pancreatectomy

verfasst von: Li Liu, Guochao Zhao, Wenchuan Wu, Yefei Rong, Dayong Jin, Dansong Wang, Wenhui Lou, Xinyu Qin

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

The prognosis for pancreatic ductal adenocarcinoma (PDAC) remains extremely poor. Recent studies have focused on the role of lymphocytes in the PDAC microenvironment. Using immunohistochemistry, our study explored the clinical significance of intratumoral or peritumoral CD4⁺Foxp3⁺ regulatory T cells (Tregs) and CD8⁺ T cells in the tumor microenvironment and analyzed their relation to the prognosis of PDAC in a consecutive series of 92 patients after resection. CD8⁺ T cells were more frequently seen within peritumoral sites, while CD4⁺Foxp3⁺ Tregs were more frequent within intratumoral areas. Neither exhibited any relationship with other clinicopathologic factors. Patients with low levels of intratumoral Tregs had longer disease-free survival than those with higher levels (DFS 22.2 vs. 11.2 months, p < 0.001), and patients with higher levels of peritumoral CD8⁺ T cells had longer overall survival than those with lower levels (OS 31.0 vs. 14.2 months, p < 0.001). Multivariate analysis demonstrated that intratumoral Tregs (hazard ratio, HR 3.39, p = 0.010) and peritumoral CD8⁺ T cells (HR 0.10, p < 0.001) are related to DFS and OS, respectively. These results indicate that intratumoral Tregs are a negative predictor of DFS, while peritumoral CD8⁺ T cells are a positive predictor of OS for PDAC patients with pancreatectomy.

Nur mit Berechtigung zugänglich

Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1):5–29. doi:10.3322/caac.21254 PubMedCrossRef

Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, Sauter PK, Coleman J, Hruban RH, Lillemoe KD (2000) Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 4(6):567–579PubMedCrossRef

Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Nakagawa N, Sasaki H, Sueda T (2013) Early initiation of adjuvant chemotherapy improves survival of patients with pancreatic carcinoma after surgical resection. Cancer Chemother Pharmacol 71(2):419–429. doi:10.1007/s00280-012-2029-1 PubMedCrossRef

Herman JM, Swartz MJ, Hsu CC, Winter J, Pawlik TM, Sugar E, Robinson R, Laheru DA, Jaffee E, Hruban RH, Campbell KA, Wolfgang CL, Asrari F, Donehower R, Hidalgo M, Diaz LA Jr, Yeo C, Cameron JL, Schulick RD, Abrams R (2008) Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol 26(21):3503–3510. doi:10.1200/JCO.2007.15.8469 PubMedPubMedCentralCrossRef

Hsu CC, Herman JM, Corsini MM, Winter JM, Callister MD, Haddock MG, Cameron JL, Pawlik TM, Schulick RD, Wolfgang CL, Laheru DA, Farnell MB, Swartz MJ, Gunderson LL, Miller RC (2010) Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital—Mayo Clinic collaborative study. Ann Surg Oncol 17(4):981–990. doi:10.1245/s10434-009-0743-7 PubMedPubMedCentralCrossRef

Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Nakashima A, Yuasa Y, Kondo N, Ohge H, Sueda T (2010) Number of metastatic lymph nodes, but not lymph node ratio, is an independent prognostic factor after resection of pancreatic carcinoma. J Am Coll Surg 211(2):196–204. doi:10.1016/j.jamcollsurg.2010.03.037 PubMedCrossRef

Winter JM, Cameron JL, Campbell KA, Arnold MA, Chang DC, Coleman J, Hodgin MB, Sauter PK, Hruban RH, Riall TS, Schulick RD, Choti MA, Lillemoe KD, Yeo CJ (2006) 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 10(9):1199–1210. doi:10.1016/j.gassur.2006.08.018 (discussion 1210–1191) PubMedCrossRef

Ino Y, Yamazaki-Itoh R, Shimada K, Iwasaki M, Kosuge T, Kanai Y, Hiraoka N (2013) Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer 108(4):914–923. doi:10.1038/bjc.2013.32 PubMedPubMedCentralCrossRef

De Monte L, Reni M, Tassi E, Clavenna D, Papa I, Recalde H, Braga M, Di Carlo V, Doglioni C, Protti MP (2011) Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 208(3):469–478. doi:10.1084/jem.20101876 PubMedPubMedCentralCrossRef

10.

Grabenbauer GG, Lahmer G, Distel L, Niedobitek G (2006) Tumor-infiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma. Clin Cancer Res 12(11 Pt 1):3355–3360. doi:10.1158/1078-0432.CCR-05-2434 PubMedCrossRef

11.

Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AY (2005) Regulatory T cell lineage specification by the forkhead transcription factor Foxp3. Immunity 22(3):329–341. doi:10.1016/j.immuni.2005.01.016 PubMedCrossRef

12.

Linehan DC, Goedegebuure PS (2005) CD25⁺CD4⁺ regulatory T-cells in cancer. Immunol Res 32(1–3):155–168PubMedCrossRef

13.

Hiraoka N, Onozato K, Kosuge T, Hirohashi S (2006) Prevalence of FOXP3⁺ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 12(18):5423–5434. doi:10.1158/1078-0432.CCR-06-0369 PubMedCrossRef

14.

Bindea G, Mlecnik B, Fridman WH, Galon J (2011) The prognostic impact of anti-cancer immune response: a novel classification of cancer patients. Semin Immunopathol 33(4):335–340. doi:10.1007/s00281-011-0264-x PubMedPubMedCentralCrossRef

15.

Ladoire S, Martin F, Ghiringhelli F (2011) Prognostic role of FOXP3⁺ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol Immunother 60(7):909–918. doi:10.1007/s00262-011-1046-y PubMedCrossRef

16.

Fridman WH, Galon J, Pages F, Tartour E, Sautes-Fridman C, Kroemer G (2011) Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res 71(17):5601–5605. doi:10.1158/0008-5472.CAN-11-1316 PubMedCrossRef

17.

Hiraoka N (2010) Tumor-infiltrating lymphocytes and hepatocellular carcinoma: molecular biology. Int J Clin Oncol 15(6):544–551. doi:10.1007/s10147-010-0130-1 PubMedCrossRef

18.

Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348(3):203–213. doi:10.1056/NEJMoa020177 PubMedCrossRef

19.

Zimmermann T, Moehler M, Gockel I, Sgourakis GG, Biesterfeld S, Muller M, Berger MR, Lang H, Galle PR, Schimanski CC (2010) Low expression of chemokine receptor CCR5 in human colorectal cancer correlates with lymphatic dissemination and reduced CD8⁺ T-cell infiltration. Int J Colorectal Dis 25(4):417–424. doi:10.1007/s00384-009-0868-y PubMedCrossRef

20.

Ikeda S, Funakoshi N, Inagaki M, Shibata T (2006) Clinicopathologic roles of tumor-infiltrating lymphocytes and CD8-positive lymphocytes in lung cancer imprint smears in squamous cell carcinoma and adenocarcinoma. Acta Cytol 50(4):423–429PubMedCrossRef

21.

Schumacher K, Haensch W, Roefzaad C, Schlag PM (2001) Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res 61(10):3932–3936PubMed

22.

Alvaro T, Lejeune M, Salvado MT, Bosch R, Garcia JF, Jaen J, Banham AH, Roncador G, Montalban C, Piris MA (2005) Outcome in Hodgkin’s lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 11(4):1467–1473. doi:10.1158/1078-0432.CCR-04-1869 PubMedCrossRef

23.

Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani H, Old LJ, Odunsi K (2005) Intraepithelial CD8⁺ tumor-infiltrating lymphocytes and a high CD8⁺/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102(51):18538–18543. doi:10.1073/pnas.0509182102 PubMedPubMedCentralCrossRef

24.

Piersma SJ, Jordanova ES, van Poelgeest MI, Kwappenberg KM, van der Hulst JM, Drijfhout JW, Melief CJ, Kenter GG, Fleuren GJ, Offringa R, van der Burg SH (2007) High number of intraepithelial CD8⁺ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res 67(1):354–361. doi:10.1158/0008-5472.CAN-06-3388 PubMedCrossRef

25.

Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, Li YW, Tang ZY (2007) Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25(18):2586–2593. doi:10.1200/JCO.2006.09.4565 PubMedCrossRef

26.

Tang Y, Xu X, Guo S, Zhang C, Tang Y, Tian Y, Ni B, Lu B, Wang H (2014) An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma. PLoS One 9(3):e91551. doi:10.1371/journal.pone.0091551 PubMedPubMedCentralCrossRef

27.

Talmadge JE, Donkor M, Scholar E (2007) Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev 26(3–4):373–400. doi:10.1007/s10555-007-9072-0 PubMedCrossRef

28.

Homma Y, Taniguchi K, Murakami T, Nakagawa K, Nakazawa M, Matsuyama R, Mori R, Takeda K, Ueda M, Ichikawa Y, Tanaka K, Endo I (2014) Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma. Ann Surg Oncol 21(2):670–676. doi:10.1245/s10434-013-3390-y PubMedCrossRef

29.

Wang RF (2006) Regulatory T cells and innate immune regulation in tumor immunity. Semin Immunopathol 28(1):17–23. doi:10.1007/s00281-006-0022-7 CrossRef

30.

Bisikirska B, Colgan J, Luban J, Bluestone JA, Herold KC (2005) TCR stimulation with modified anti-CD3 mAb expands CD8⁺ T cell population and induces CD8⁺CD25⁺ Tregs. J Clin Invest 115(10):2904–2913. doi:10.1172/JCI23961 PubMedPubMedCentralCrossRef

31.

Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528):568–571. doi:10.1038/nature13954 PubMedPubMedCentralCrossRef

32.

Mellor-Heineke S, Villanueva J, Jordan MB, Marsh R, Zhang K, Bleesing JJ, Filipovich AH, Risma KA (2013) Elevated granzyme B in cytotoxic lymphocytes is a signature of immune activation in hemophagocytic lymphohistiocytosis. Front Immunol 4:72. doi:10.3389/fimmu.2013.00072 PubMedPubMedCentralCrossRef

33.

Nowacki TM, Kuerten S, Zhang W, Shive CL, Kreher CR, Boehm BO, Lehmann PV, Tary-Lehmann M (2007) Granzyme B production distinguishes recently activated CD8(+) memory cells from resting memory cells. Cell Immunol 247(1):36–48PubMedPubMedCentralCrossRef

34.

Hodge G, Barnawi J, Jurisevic C, Moffat D, Holmes M, Reynolds PN, Jersmann H, Hodge S (2014) Lung cancer is associated with decreased expression of perforin, granzyme B and interferon (IFN)-gamma by infiltrating lung tissue T cells, natural killer (NK) T-like and NK cells. Clin Exp Immunol 178(1):79–85. doi:10.1111/cei.12392 PubMedPubMedCentralCrossRef

35.

Salama P, Phillips M, Platell C, Iacopetta B (2011) Low expression of granzyme B in colorectal cancer is associated with signs of early metastastic invasion. Histopathology 59(2):207–215. doi:10.1111/j.1365-2559.2011.03915.x PubMedCrossRef

36.

Polcher M, Braun M, Friedrichs N, Rudlowski C, Bercht E, Fimmers R, Sauerwald A, Keyver-Paik MD, Kubler K, Buttner R, Kuhn WC, Hernando JJ (2010) Foxp3(+) cell infiltration and granzyme B(+)/Foxp3(+) cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma. Cancer Immunol Immunother 59(6):909–919. doi:10.1007/s00262-010-0817-1 PubMedCrossRef

37.

Kontani K, Sawai S, Hanaoka J, Tezuka N, Inoue S, Fujino S (2001) Involvement of granzyme B and perforin in suppressing nodal metastasis of cancer cells in breast and lung cancers. Eur J Surg Oncol 27(2):180–186. doi:10.1053/ejso.2000.1060 PubMedCrossRef

38.

Fritsch K, Finke J, Grullich C (2013) Suppression of granzyme B activity and caspase-3 activation in leukaemia cells constitutively expressing the protease inhibitor 9. Ann Hematol 92(12):1603–1609. doi:10.1007/s00277-013-1846-6 PubMedCrossRef

39.

Ray M, Hostetter DR, Loeb CR, Simko J, Craik CS (2012) Inhibition of granzyme B by PI-9 protects prostate cancer cells from apoptosis. Prostate 72(8):846–855. doi:10.1002/pros.21486 PubMedPubMedCentralCrossRef

40.

Prado-Garcia H, Romero-Garcia S, Aguilar-Cazares D, Meneses-Flores M, Lopez-Gonzalez JS (2012) Tumor-induced CD8⁺ T-cell dysfunction in lung cancer patients. Clin Dev Immunol 2012:741741. doi:10.1155/2012/741741 PubMedPubMedCentralCrossRef

41.

Lyman MA, Aung S, Biggs JA, Sherman LA (2004) A spontaneously arising pancreatic tumor does not promote the differentiation of naive CD8⁺ T lymphocytes into effector CTL. J Immunol 172(11):6558–6567PubMedCrossRef

Titel: Low intratumoral regulatory T cells and high peritumoral CD8+ T cells relate to long-term survival in patients with pancreatic ductal adenocarcinoma after pancreatectomy
verfasst von: Li Liu
Guochao Zhao
Wenchuan Wu
Yefei Rong
Dayong Jin
Dansong Wang
Wenhui Lou
Xinyu Qin
Publikationsdatum: 01.01.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 1/2016
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-015-1775-4

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Low intratumoral regulatory T cells and high peritumoral CD8⁺ T cells relate to long-term survival in patients with pancreatic ductal adenocarcinoma after pancreatectomy

Abstract

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2016

Aminoacyl-tRNA synthetase-interacting multifunctional protein 1 suppresses tumor growth in breast cancer-bearing mice by negatively regulating myeloid-derived suppressor cell functions

Metastatic spread in patients with non-small cell lung cancer is associated with a reduced density of tumor-infiltrating T cells

A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites

Developments in cancer vaccines for hepatocellular carcinoma

Phloretin increases the anti-tumor efficacy of intratumorally delivered heat-shock protein 70 kDa (HSP70) in a murine model of melanoma

Immunotherapy with dendritic cells loaded with glioblastoma stem cells: from preclinical to clinical studies

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie